Orca-T

A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
80 patients (estimated)
Sponsors
Orca Biosystems, Inc.
Tags
Allogeneic Stem Cell Transplant, T Cell (Allogeneic)
Trial Type
Treatment
Last Update
SparkCures ID
2182
NCT Identifier
NCT07216443

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.